These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35743735)

  • 1. Genetic Variations of the
    Farinango C; Gallardo-Cóndor J; Freire-Paspuel B; Flores-Espinoza R; Jaramillo-Koupermann G; López-Cortés A; Burgos G; Tejera E; Cabrera-Andrade A
    J Pers Med; 2022 Jun; 12(6):. PubMed ID: 35743735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-Specific Distribution of
    Gallardo-Cóndor J; Naranjo P; Atarihuana S; Coello D; Guevara-Ramírez P; Flores-Espinoza R; Burgos G; López-Cortés A; Cabrera-Andrade A
    Ther Clin Risk Manag; 2023; 19():1005-1018. PubMed ID: 38050617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of ancestry informative markers in three main ethnic groups from Ecuador supports a trihybrid origin of Ecuadorians.
    Santangelo R; González-Andrade F; Børsting C; Torroni A; Pereira V; Morling N
    Forensic Sci Int Genet; 2017 Nov; 31():29-33. PubMed ID: 28826061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.
    Del Re M; Cinieri S; Michelucci A; Salvadori S; Loupakis F; Schirripa M; Cremolini C; Crucitta S; Barbara C; Di Leo A; Latiano TP; Pietrantonio F; Di Donato S; Simi P; Passardi A; De Braud F; Altavilla G; Zamagni C; Bordonaro R; Butera A; Maiello E; Pinto C; Falcone A; Mazzotti V; Morganti R; Danesi R
    Pharmacogenomics J; 2019 Dec; 19(6):556-563. PubMed ID: 30723313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of the molecular variants associated with lactase persistence in different Ecuadorian ethnic groups.
    Paz-Y-Miño C; Burgos G; López-Cortés A; Herrera C; Gaviria A; Tejera E; Cabrera-Andrade A
    Am J Hum Biol; 2016 Nov; 28(6):774-781. PubMed ID: 27153930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
    Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
    Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (
    Soria-Chacartegui P; Villapalos-García G; López-Fernández LA; Navares-Gómez M; Mejía-Abril G; Abad-Santos F; Zubiaur P
    Pharmaceutics; 2021 Nov; 13(12):. PubMed ID: 34959317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study.
    Miarons M; Manzaneque Gordón A; Riera P; Gutiérrez Nicolás F;
    Oncologist; 2023 May; 28(5):e304-e308. PubMed ID: 37014829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.
    Henricks LM; Opdam FL; Beijnen JH; Cats A; Schellens JHM
    Ann Oncol; 2017 Dec; 28(12):2915-2922. PubMed ID: 29045513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments.
    Bruera G; Ricevuto E;
    Pharmgenomics Pers Med; 2020; 13():601-617. PubMed ID: 33235483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol.
    Hernández-Guío A; Bernabéu-Martínez MªÁ; Corno-Caparrós A; Aznar-Saliente MªT; Bonete-Sánchez M; Calleja-Hernández MÁ
    Farm Hosp; 2021 Apr; 45(3):155-159. PubMed ID: 33941060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.
    Froehlich TK; Amstutz U; Aebi S; Joerger M; Largiadèr CR
    Int J Cancer; 2015 Feb; 136(3):730-9. PubMed ID: 24923815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic DPYD allele variant frequencies: A comprehensive analysis across an ancestrally diverse Iranian population.
    Sarhangi N; Rouhollah F; Niknam N; Sharifi F; Nikfar S; Larijani B; Patrinos GP; Hasanzad M
    Daru; 2024 Dec; 32(2):715-727. PubMed ID: 39424756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Characterization of 21 Allelic Variants of Dihydropyrimidine Dehydrogenase Identified in 1070 Japanese Individuals.
    Hishinuma E; Narita Y; Saito S; Maekawa M; Akai F; Nakanishi Y; Yasuda J; Nagasaki M; Yamamoto M; Yamaguchi H; Mano N; Hirasawa N; Hiratsuka M
    Drug Metab Dispos; 2018 Aug; 46(8):1083-1090. PubMed ID: 29769267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
    Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.
    Meulendijks D; Henricks LM; Amstutz U; Froehlich TK; Largiadèr CR; Beijnen JH; de Boer A; Deenen MJ; Cats A; Schellens JH
    Int J Cancer; 2016 Jun; 138(11):2752-61. PubMed ID: 26804235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving single nucleotide polymorphisms genotyping accuracy for dihydropyrimidine dehydrogenase testing in pharmacogenetics.
    Montella A; Cantalupo S; D'Alterio G; Damiano V; Iolascon A; Capasso M
    Explor Target Antitumor Ther; 2024; 5(2):374-383. PubMed ID: 38745766
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    de With M; Brufau G; van den Berg LA; de Man FM; Trajkovic M; Thijs MF; Castel R; Vermeer HJ; El Bouazzaoui S; van Hemel A; Matic M; Mathijssen RHJ; Bins S; van Schaik RHN
    JCO Precis Oncol; 2022 Jul; 6():e2200180. PubMed ID: 35862869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.
    Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; van Werkhoven E; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
    Eur J Cancer; 2019 Jan; 107():60-67. PubMed ID: 30544060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of DPYD gene variants and phenotype inference in a Southern Brazilian population.
    Botton MR; Hentschke-Lopes M; Matte U
    Ann Hum Genet; 2022 Mar; 86(2):102-107. PubMed ID: 34897655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.